Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Adalimumab; Antibodies; Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Moderate to severe PsA

• Inadequate response to DMARD therapy

• Corticosteroid stable dose <= 10 mg QD

• DMARDs must have been taken for 3 months and stable dose for 4 weeks

• MTX maximum dose = <= 30 mg/week

• Active chronic plaque PS or documented history of chronic plaque PS

Exclusion Criteria:

• No other active skin disease